We examined four different cannabinergic aminoalkylindole ligands, including one drug (AM678 = JWH018) found in herbal 'Spice' concoctions, for their ability to substitute for D 9 -tetrahydrocannabinol (THC), and the ability of the cannabinoid receptor 1-selective antagonist/inverse agonist rimonabant to block the substitution, 30 and 90 min after intraperitoneal injection. Rats trained to discriminate the effects of vehicle from those produced by 3 mg/kg of THC were used. The order of potency was: AM5983 Z AM678 > AM2233 > WIN55212-2 at both test intervals. AM5983 and AM678 appeared eight times more potent than THC, followed by AM2233 (about twice as potent as THC), and WIN55212-2 approximately THC at the 30-min test interval. The aminoalkylindoles showed reduced potency (i.e. an increased ED 50 value) at the longer injection-to-test interval of 90 min compared with testing at 30 min. The rightward shifts by coadministration of rimonabant were approximately 8-fold to 12-fold for AM5983 and AM678, compared with an approximately 3-fold rightward shift for the WIN55212-2 curve. AM2233 (1.8 mg/kg) substitution was also blocked by 1 mg/kg of rimonabant. In conclusion, AM5983 and AM678 = JWH018 are potent cannabimimetics derived from an aminoalkylindole template. WIN55212-2 seemed to interact differently with rimonabant, compared with either AM5983 or AM678, indicating potential differences in the mechanism(s) of action among cannabinergic aminoalkylindoles. Behavioural Pharmacology 22:498-507
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Introduction
The endocannabinoid system (ECS) has emerged as a regulatory system of major significance for both normal physiology and pathophysiology. The system consists of two cloned G-protein-coupled seven transmembrane receptors, namely, cannabinoid receptor 1 (CB 1 R) and 2 (CB 2 R) and endogenous ligands. CB 1 R/CB 2 R binds the phytocannabinoid D 9 -tetrahydrocannabinol (THC), the main psychoactive constituent in preparations derived from Cannabis sativa L. The activation of CB 1 R seems to be primarily responsible for the 'subjective high'. Thus, ECS can be affected by both endogenous and exogenous ligands. Apart from issues related to drug abuse and dependence, ECS has also been implicated in various other pathophysiological states, for example, chronic pain and inflammation; for overview, see Pertwee (2010) .
The first cannabinergic indoles to be discovered were aminoalkylindoles, of which WIN55212-2 was the most potent in vivo (Compton et al., 1992) , and this ligand has subsequently been widely used as a tool in cannabinoid research. Given the emphasis on CB 2 R activation/ inactivation as therapeutics (Poso and Huffman, 2008) and the status of WIN55212-2 as a relatively readily available 'prototypical' CB 1 R agonist, pharmacological information on other cannabimimetic indoles is scant and typically limited to binding assays regarding cannabinoid receptor affinity and subtype selectivity. Depending on the training drug used for discrimination (THC or methanandamide, a stable analog of the endogenous ligand anandamide), we previously observed different magnitudes of rightward shifts of the dose-effect curves for the aminoalkylindoles, WIN55212-2 and AM678, in the presence of the selective CB 1 R antagonist/inverse agonist rimonabant, suggesting potential differences in the mode of action between the two indoles (Järbe et al., 2010) . Although the underlying mechanism for this differential effect is unknown, there are several instances in which divergent effects on signaling and cellular/ physiological responses between WIN55212-2 and THC (or CP55940) have been reported (Bosier et al., 2010) .
Direct CB 1 R activation can produce pronounced psychotropic effects and therefore other approaches have been pursued for developing therapeutics potentially affecting the ECS. Yet, it has become increasingly clear that a clandestine market has developed surrounding synthetic alternatives for achieving marijuana-like effects. It is also from this perspective that more in-vivo information about cannabimimetic designer drugs is relevant. One of the currently examined compounds (AM678) is/was commonly used as an adulterant in herbal preparations such as 'Spice', which was initially offered primarily in Europe and also presented as a legal alternative to marijuana (Hudson et al., 2010; Vardakou et al., 2010) . This aminoalkylindole is more commonly known in the scientific literature as JWH018 (Huffman et al., 1994) . Initial in-vivo studies showed the compound to be effective in the so-called 'tetrad' battery of tests in mice (Wiley et al., 1998) , and also in drug discrimination for rats, differentiating between vehicle and either THC or methanandamide (Järbe et al., 2010) . In both studies, indications of differences between agonists were obtained, although the ligands exhibited a general cannabimimetic profile. Atwood et al. (2010) examined the signaling characteristics of the drug at CB 1 R and concluded that 'JWH018 is a potent and efficacious CB 1 R agonist'.
The current studies examined four cannabinergic aminoalkylindoles, including WIN55212-2, for their ability to substitute for THC, and their interaction with rimonabant, in rats discriminating a higher dose of THC compared with the earlier report, as training dose can be an important determinant in drug discrimination (Järbe, 1989) , both in terms of efficacy and mechanism of action (Bergman et al., 2000; Hodge et al., 2006) . Information on the duration of effect for indole-derived cannabinergics is very limited. To gauge duration of action, the currently examined aminoalkylindoles were tested at both 30 and 90-min postadministration to ensure that our protocol included an injection-to-test interval, at which maximum in-vivo activity would be sampled (see below, Methods). THC discrimination is a pharmacologically selective animal model involving CB 1 R activation (Järbe, 2011) . Thus, the 'perceived' effects of THC define the endpoint by which new compounds are evaluated.
Methods

Subjects
Two separate groups of eight and 12 male Sprague-Dawley rats (Taconic Farms, Germantown, New York, USA) were used. Subjects were individually housed in colony rooms with an average temperature of 201C and a 12-h light/dark cycle (rats were trained and tested during the light phase). Subjects (approximately 90 days old at purchase) were experimentally naïve at the time of shaping the lever pressing response (see below). Postsession supplemental feeding with Harlan Rat Chow (2018) was restricted to approximately 12-14 g per day. All procedures were approved by the Animal Care and Use Committee of Hahnemann University/Allegheny Research Foundation (now Drexel University; n = 8) and that of Temple University (n = 12), Philadelphia, Pennsylvania, USA. The 'Principles of Animal Laboratory Care' (National Institutes of Health, 1996) were followed.
Apparatus
Training and testing occurred in eight chambers (ENV-001, Med. Associates, St Albans, Vermont, USA) equipped with two nonretractable response levers, house and lever lights, and a grid floor. Each chamber was enclosed within a soundattenuating and light-attenuating box with an exhaust fan and interfaced with a DOS/Windows compatible computer. Response contingencies were programmed using Med-PC software (v. 1.16; Med. Associates).
Training procedure
Rats were trained to eat food pellets (45 mg, BioServe, Frenchtown, New Jersey, USA) from a food receptacle located midway between the two response levers, and shaped to lever press for food until responding 10 times for each reinforcer [fixed-ratio 10 schedule of reinforcement (FR-10)]. When the house light was off, and the stimulus lights above the response levers were lit, completion of 10 presses on the state-appropriate lever resulted in the delivery of two food pellets (45 mg), followed by 10-sec (n = 8) or 6-sec (n = 12) time-out period with only the house light on. At the end of the time-out period, the stimulus lights above the levers were lit, the house light was turned off, and the FR-10 schedule of reinforcement contingency was reinstated. Sessions ended by all lights in the box being turned off.
Once daily, beginning 30 min (n = 8) or 20 min (n = 12) after intraperitoneal injection, the rats were trained in this two-choice task to respond on drug-associated (3 mg/kg of THC) or vehicle-associated levers. The change from 30 to 20-min postinjection training interval was for logistical reasons (Järbe et al., 2001) . The position of drugappropriate levers was randomly assigned among rats so that it was to the right of the food cup for half the subjects and left for the other half. Throughout the session, the aforementioned FR-10 reinforcement schedule was in effect. Presses on the incorrect lever were recorded, but had no programmed consequences. The order of drug or vehicle administrations was nonsystematic, with no more than two consecutive drug or vehicle sessions. Approximately, an equal number of drug and vehicle training sessions occurred throughout the study. To avoid the potential influence of odor cues left in a chamber by a preceding subject, the order in which drug/ vehicle training sessions were conducted for rats trained in the same chamber was randomized (Extance and Goudie, 1981) . Training occurred from Monday to Friday, and lasted for 20 min. Training continued until and beyond the point at which rats reached the acquisition criterion of selecting the lever appropriate for the training condition on at least eight of 10 consecutive sessions. Correct selection was defined as total presses before the first reinforcement (FRF) being equal to, or less than 14 (i.e., the incorrect lever not pressed more than four times before completing 10 presses on the lever appropriate for the prevailing training condition; FRF r 14).
Testing procedure
Once stable THC (3 mg/kg) discriminations were achieved (see Results), test sessions were conducted on average three times every 2 weeks; on interim days, regular drug or vehicle training sessions of 20-min duration took place. Approximately, 2 weeks before initial testing, subjects began receiving two intraperitoneal injections (2 ml/kg each) before the training sessions (i.e., drug and vehicle, or vehicle and vehicle) to accustom the subjects to a double injection procedure such as that used for antagonism testing. Typically, the order of sessions was: drug, vehicle, test, vehicle, drug (week 1); vehicle, test, vehicle, drug, test (week 2); vehicle, drug, test, drug, vehicle (week 3); and drug, test, drug, vehicle, test (week 4). Tests were conducted only if responding during the training sessions immediately preceding the test had been correct (FRF r 14) during the initial six FR-10 cycles of the session. If incorrect, subjects were retrained for at least three sessions, at which FRF of less than or equal to 14 before additional testing took place. In test sessions, food pellets were delivered for 10 presses on either lever for six reinforcement cycles or until 20 min had elapsed, whichever occurred first. There were one (THC) or two (aminoalkylindoles) sessions per test day. In the case of two test sessions, subjects finished the first test at 30-min postinjection as described above, then were put back in their home cages and left undisturbed until being put back into the chambers for the second test probe occurring 90-min postinjection, which was executed as described above. These intervals were based on the timecourse data for WIN55212-2 (Pério et al., 1996) and our previous study regarding WIN55212-2 and AM678 (Järbe et al., 2010). Doses and drugs were examined in a mixed order. For each dose tested, the percentage of responding on the drug-appropriate lever was calculated from the ratio of the number of presses on the drug (THC)associated lever to the total number of lever presses in a test session (excluding responding during the time-out periods). Only data for subjects receiving at least one reinforcer during the test session were considered for this measure, that is, subjects must have made a minimum of 10 presses on one of the two levers. Response rate (responses per second) across all subjects was also calculated. This measure was based on the performance of all rats, including nonresponders.
Data analysis
Response rate was averaged [± standard error of the mean (SEM)] among rats and was plotted as a function of dose. The effects of a drug on response rate were considered significant when the mean rate of responding was not within the 95% confidence limits (± 95% CL) of the mean control response rate, expressed as a percentage [rate (% control)]. This was defined in individual rats as the mean response rate pertaining to the initial six reinforcement cycles, calculated from vehicle training sessions, in which the criteria for testing were met. The dotted horizontal lines in the graphs presented in 'Results' represent the ± 95% CL of the percentage vehicle rate immediately preceding the tests in question. Data points outside these dotted lines are considered significant. Nonlinear regression analyses of the average generalization and antagonism data after log-dose transformation were performed using Prism software (v. 5, GraphPad Software, San Diego, California, USA) to provide ED 50 estimates and their ± 95% CL (regression model: log dose vs. response -variable slope with the top and bottom of the curves constrained to 100 and 0). Using the F-test, the Prism program estimates whether slopes are parallel, and if parallel, evaluates whether the intercepts are equal (a measure of potency).
Drugs
The levo isomer of D 9 -THC (6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol), dissolved in ethanol (200 mg/ml), was kindly provided by the National Institute on Drug Abuse (NIDA; Bethesda, Maryland, USA) and stored at -201C until used. To prepare suspensions, appropriate amounts of ethanol/ THC were withdrawn, the ethanol evaporated under a stream of nitrogen, and the residue dissolved (w/v) in a solution of propylene glycol (PG) and Tween-80 (T-80), before the solute was diluted with normal (0.9%) saline after sonication for 20 min. Rimonabant, as base (N-(piperidin-1-yl)-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide) was also provided by NIDA and was stored under refrigeration at 41C before being dissolved in the PG/T-80 (v/v) mixture and diluted with saline. For the most part, the final suspension consisted of 5% PG/ 3% T-80 and 92% saline, the exceptions being the three highest doses of WIN55212-2 (5.6, 10, and 18 mg/kg) and the highest doses of AM678 (3 mg/kg) and AM5983 (3 mg/kg), at which 5% T-80 were used, that is, 5, 5, and 90%, respectively. (R)-(+)-WIN55212-2 mesylate [(R)-(5-methyl-3-(morpholinomethyl)-2,3-dihydro-[1,4]oxazino[2,3,4-hi]indol-6-yl)(naphthalen-1-yl)methanone; K i (CB 1 ) = 1.9 nmol/l; K i (CB 2 ) = 0.3 nmol/l; purity Z 98%] was purchased from Biomol (Plymouth Meeting, Pennsylvania, USA); K i values for WIN were obtained from published literature (Thakur et al., 2005) . AM678 [naphthalen-1-yl(1-pentyl-1H-indol-3-yl)methanone; K i (CB 1 ) = 4.5 nmol/l; K i (CB 2 ) = 33.6 nmol/l; MW = 341], (±) AM5983 [(1-((1-methylpiperidin-2-yl)methyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone; K i (CB 1 ) = 2.1 nmol/l; K i (CB 2 ) = 2.3 nmol/l; MW = 383] and (±) AM2233 {(2-iodophenyl){1-[(1methylpiperidin-2-yl)methyl]-1H-indol-3-yl}methanone: K i (CB 1 ) = 2.9 nmol/l; K i (CB 2 ) = 3.3 nmol/l; MW = 458} are crystalline compounds that were handled the same way as rimonabant and WIN55212-2. The ligands AM678, AM5983, and AM2233 were synthesized in the Center for Drug Discovery, University of Connecticut at Storrs; for structures, see Figure 1 . Doses were generally administered intraperitoneally in a volume of 2 ml/kg, the exceptions being the two highest doses of WIN55212-2 (10 and 18 mg/kg), where 3 ml/kg was used. Suspensions were prepared fresh daily just before the administration. Doses are expressed as the forms indicated. The smallsize THC group (n = 8) examined the effects of AM678 and AM5983 alone in addition to generating the THC generalization gradient at 30-min postinjection. The other group (n = 12) was used for all other tests.
Results
The 12 rats used to generate most of the current data were trained to discriminate between THC and vehicle for 37 sessions on the terminal FR-10 schedule of reinforcement before testing commenced; the other eight rats were discrimination trained for 41 sessions before being subjected to testing.
Tetrahydrocannabinol Figure 2 illustrates the generalization gradients (doseresponse curves) for THC itself in subjects discriminating between 3 mg/kg of THC and vehicle, administered intraperitoneally either 30 min (circles; n = 8), or 20 min (hexagons; n = 12) before session onset. The ED 50 estimates and the ± 95% CL are indicated in the upper graph. Neither the ED 50 values nor the Hill slopes were significantly different between the two data sets [F(2,6) = 3.50; not significant]. When combined, the average ED 50 value (± 95% CL) was 1.12 mg/kg (0.96-1.31 mg/kg; Table 1 ) and the corresponding values for Hill slope were: 2.95
(1. 75-4.16 ). The rate of responding during these tests is indicated in the lower panel. Most of the latter data points were within or in close proximity to the ± 95% CL of the combined vehicle baseline data for the two groups of rats.
Aminoalkylindoles Figures 3 and 4 illustrate the generalization gradients (dose-response curves) for WIN55212-2, AM678, AM5983, and AM2233 alone (open symbols), and when tested together with 1 mg/kg of rimonabant (filled symbols) at 30 min ( Fig. 3 ) and 90 min (Fig. 4 ) postinjection in rats discriminating between 3 mg/kg of THC and vehicle. The ED 50 estimates and the ± 95% CL are indicated in Table 1 (the data point in the left panel of Fig. 3 reflecting two responding rats of 12 rats tested at 5.6 mg/kg of WIN55212-2 alone at 30-min postadministration, is not included in the regression analysis). The lower panels of each figure indicate the associated rates of responding, expressed as a percentage of the control rate obtained from the vehicle training sessions immediately preceding these tests.
WIN55212-2
As indicated in the upper left panels of Figures 3 and 4 and as detailed in Table 1 , the ED 50 estimates for WIN55212-2 alone differed significantly between the tests occurring 30 min compared with 90-min postadministration (no overlapping values within the ± 95% CL), as did the Hill slopes [F(1,9) = 7.02; P < 0.05]. Coadministration of 1 mg/kg of rimonabant shifted the generalization gradients of WIN55212-2 significantly to the right as there were no overlaps in the ED 50 (± 95% CL) values for the two test intervals, that is, 30 min ( Fig. 3 ) and 90 min (Fig. 4) postadministration. Similar to WIN55212-2 alone, there was also a tendency for reduced THC-like responding for the longer compared with the shorter test interval in the drug combination tests (upper left panels of Figs 3 and 4) . Response rates for these tests are shown in the two lower left panels of Figures 3 and 4 . Most of these data points were within or in close proximity to the ± 95% CL of the vehicle baseline data, exceptions being the effects resulting from the higher test doses of WIN55212-2 alone and the rimonabant and WIN55212-2 combination at both injection-test intervals.
AM678
The next left panels of Figures 3 and 4 illustrate the generalization gradients for AM678 alone (open symbols), and when tested together with 1 mg/kg of rimonabant (filled symbols). AM678 alone potently substituted for THC at the 30-min postinjection test (Fig. 3) ; the THClike cue effect was reduced at the 90-min test (Fig. 4) . Coadministration of 1 mg/kg of rimonabant shifted the generalization gradient of AM678 to the right at both test intervals ( Table 1 ). The response rates during these tests are indicated in the two lower panels (AM678 alone, open symbols and rimonabant and AM678, filled symbols). Most of these data points were within or in close proximity to the ± 95% CL of the vehicle baseline data, the exception being the highest test dose of AM678 (3 mg/kg) in combination with rimonabant (lower section of Fig. 4 ).
AM5983
The next third set of panels of Figures 3 and 4 illustrate the generalization gradients for AM5983 alone (open symbols), and when examined together with 1 mg/kg of rimonabant (filled symbols). AM5983 alone potently substituted for THC at both the 30 min ( Fig. 3 ) and the 90 min ( Fig. 4 ) postinjection tests. Coadministration of 1 mg/kg of rimonabant resulted in at least 10-fold parallel shifts to the right of the AM5983 generalization gradients (Table 1) . Response rates for these tests are shown in the two lower sections of Figures 3 and 4 . With the exception of 1 mg/kg of AM5983 examined alone, most data points were within or in close proximity to the ± 95% CL of the vehicle baseline data. the two highest doses at 30 min and remained so for the 1.8-mg/kg dose also at 90-min postinjection. Although 1 mg/kg of rimonabant attenuated the degree of substitution at 30 min (Fig. 3, upper right panel) , the ratedecreasing effects of 1.8 mg/kg of AM2233 were not blocked (Fig. 3, lower right panel) . However, the rate decrease was blocked at the 90-min test (Fig. 4) , that is, the rate being within the ± 95% CL of the vehicle baseline data. All subjects (n = 12) obtained at least one reinforcement during both tests.
Discussion
To summarize, coadministration of rimonabant (1 mg/kg) resulted in wider rightward shifts of the AM678 and AM5983 generalization curves compared with that of 
AM2233
Generalization test results (upper panels) and the corresponding response rate data (lower panels) for the test drug alone (open triangles; WIN55212-2 n = 12; AM678 n = 6-7; AM5983 n = 7; and AM2233 n = 10-12), and when combined with 1 mg/kg of rimonabant (filled triangles; WIN55212-2 n = 11-12; AM678 n = 11-12; AM5983 n = 11-12; and AM2233 n = 12), 30 min postintraperitoneal administration. Drug-lever responding results (upper panels) represent the mean [ ± standard error of the mean (± SEM)] percentage of lever presses on the THC appropriate lever of the total number of lever presses emitted during a test session (vertical axis); doses examined in mg/kg (horizontal axis). Rate refers to the mean (± SEM) number of lever presses per second emitted during a test session (vertical axis); doses in mg/kg (horizontal axis). Numbers within brackets indicate the number of rats responding (i.e., accumulating at least 10 responses on either lever and thus obtaining at least one reinforcement) out of the total number used for the test. Other details are as described in the legend for Fig. 2 .
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WIN55212-2. All four aminoalkylindoles exhibited less THC-like cue effects at 90 min compared with the results from the 30-min postadministration interval. Irrespective of the time interval studied, the following rank order of potency emerged: AM5983 Z AM678 > AM2233 > WIN55212-2. On the basis of data from the shorter injection-to-test interval, AM5983 and AM678 appeared eight times more potent than THC, followed by AM2233, which was about twice as potent as THC, and THC Z WIN55212-2. All of these ligands showed a reduced potency (i.e., an increased ED 50 value) at the longer injection-to-test interval of 90 min compared with the initial tests conducted at 30 min. Such a decline over time in the ability to substitute for THC was also evident from tests involving antagonism of these ligands by rimonabant. The rightward shifts caused by rimonabant were more pronounced for AM5983 and AM678 compared with WIN55212-2, and of similar magnitude to that described earlier for THC/rimonabant combinations, that is, approximately 8-fold to 12-fold based on data from the shorter injection-to-test interval of 30 min (Järbe et al., 2001) . In contrast, there was only an approximately 3-fold rightward shift of the WIN55212-2 curve, consistent with previous data (Järbe et al., 2010) using a lower training dose of THC (1.8 mg/kg), and hence extending the generality of this outcome by a systematic replication approach (Sidman, 1960) .
WIN55212-2 has been characterized in vitro as a full CB 1 R agonist, and the ligand generally is considered more potent than the partial CB 1 R agonist THC (Pertwee, 2008) . This contention was supported also by some early Generalization test results (top) for the test drug alone (open triangles) and when combined with 1 mg/kg of rimonabant (filled triangles) and the corresponding response rate data (bottom), 90 min postintraperitoneal administration. The 90-min test occurred subsequent to the 30-min test after a single injection and hence both intervals evaluated during the same test day. Drug-lever responding results represent the mean [ ± standard error of the mean (± SEM)] percentage of lever presses on the THC appropriate lever of the total number of lever presses emitted during a test session (vertical axis); doses examined in mg/kg (horizontal axis). Rate refers to the mean (± SEM) number of lever presses per second emitted during a test session (vertical axis); doses in mg/kg (horizontal axis). The 90-min test occurred subsequent to the 30-min test after a single injection and hence both intervals evaluated during the same test day. Other details are as described in the legend for Figs 2 and 3. drug discrimination studies (Compton et al., 1992; Pério et al., 1996) and later investigations (McMahon et al., 2008; Solinas et al., 2007) . However, other studies, similar to this one, have not necessarily found that to be the case; see also (Wiley et al., 1995; Mauler et al., 2002; Jentzsch, 2002, 2004; McMahon, 2006a McMahon, , 2006b Järbe et al., 2010) . Although the reason for this discrepancy in relative potency across studies is not known, it is noteworthy that WIN appeared less effective than either of the CB 1 R agonists THC or CP55940 in attenuating or reversing the discriminative stimulus effects of rimonabant in monkeys maintained on twice/daily THC administration (Stewart and McMahon, 2010) . Thus, such an outcome from this presumed withdrawal discrimination seems to support the contention that there are differences in the way that CB 1 R agonists interact with rimonabant and hence suggests differences in the mode(s) of action [see also (McMahon, 2006b) ].
The decline in the percent of drug responding between the 30 and 90-min test intervals suggests that the THClike effects of WIN55212-2 have a relatively fast offset.
Although not re-examined here, previous data (Järbe et al., 1986) suggested that for THC itself, the difference between these two intervals was less pronounced.
Using the same regression model as that applied here resulted in ED 50 (± 95% CL) estimates of 0.85 mg/kg (± 0.63-1.16 mg/kg) and 1.06 mg/kg (0.82-1.37 mg/kg) of THC for these two injection-to-test intervals, respectively (Järbe et al., 1986) . In addition, applying the current nonlinear regression model to the time-course data generated by rats discriminating WIN55212-2 (0.3 mg/kg) from vehicle produced an in-vivo functional half-life estimate of (± 95% CL) 129.9 min (± 120.1-140.4 min), again suggesting a relatively short duration of action (Pério et al., 1996) . As for THC, the discriminative stimulus effects of this CB 1 R agonist are clearly reduced 4 h after intraperitoneal administration in rats (Järbe et al., 1981 (Järbe et al., , 1986 .
At both test intervals examined, coadministration of rimonabant (1 mg/kg) and WIN55212-2 shifted the CB 1 R agonist generalization/dose gradient approximately 3-fold to the right, which is indicative of surmountable antagonism. That increasing doses of WIN55212-2 can overcome the rimonabant-induced CB 1 R blockade is consistent with previous findings, although the magnitude of the shift has varied (Järbe et al., 2010; McMahon, 2006a; Wiley et al., 1995) . The current magnitude of the right-fold shift of the WIN55212-2 curve is similar to the 2.5-fold shift we observed in rats trained to discriminate between vehicle and 1.8 mg/kg of THC (Järbe et al., 2010) , and furthermore contrasts with the larger rightward displacement that occurred with rimonabant/AM678 combinations as reported previously (Järbe et al., 2010) , as well as in this study. The latter magnitude of the displacement of the dose-response curve was evident also for AM5983/rimonabant combinations. Both AM678 and AM5983 were approximately eight times more potent than THC, and by extension also WIN55212-2. Although we are cognizant that many factors determine in-vivo potency, receptor affinity could explain the relative potency difference between THC [K i (CB 1 ) = 46 nmol/l] and AM678 [K i (CB 1 ) = 4.5 nmol/l] as well as AM5983 [K i (CB 1 ) = 2.1 nmol/l], but does not account for the diminished relative potency of WIN55212-2 [K i (CB 1 ) = 1.9 nmol/l] as a substitute for THC. It has been argued that the mode of CB 1 R activation is different for aminoalkylindoles compared with that of more 'classical' cannabinergics such as THC and the potent analog CP55940 (Huffman and Padgett, 2005; Manera et al., 2008) . Regardless, the current studies reaffirmed the previously reported activity of AM678, both when examined alone and when combined with rimonabant, by extending the finding to a situation involving a higher training dose and presumably therefore a more salient THC cue. An in-vivo activity profile similar to AM678 was evident also for AM5983 in this study.
The aminoalkylindole, AM2233, was developed as a potent CB 1 R (racemic K i = 2.8 nmol/l) agonist and as a probe for biochemical and imaging studies (Deng et al., 2005) . Radioiodinated [ 131 I]AM2233 followed a brain distribution pattern consistent with anatomical areas known to display an abundance of CB 1 R expression and it was more potent than WIN55212-2 (Deng et al., 2005) . Therefore, it is not surprising that AM2233 substituted for the discriminative stimulus effects of THC. In this regard, the compound was twice as potent as THC (and WIN55 212-2) at the 30-min injection-to-test interval. Very limited THC-like responding occurred when testing the subjects 90 min after injection, suggesting a comparatively short duration of action for the THC-like effects of AM2233. Similarly, a short duration of action of the primary active isomer R-[ 131 I]AM2233 was evident also in brain binding studies in mice, in which the highest activity was registered 5 min intravenously postinjection with very little activity remaining 60 min later (Dhawan et al., 2006) . In agreement with the above reports, the substitution for THC by AM2233 was rimonabant sensitive. Thus, coadministration of rimonabant together with a high dose of AM2233 (1.8 mg/kg) markedly attenuated the degree of substitution at both postinjection intervals, suggesting CB 1 R mediation for the THClike effects of AM2233.
Two of the four aminoalkylindoles examined here are racemic mixtures. For AM2233, most of the CB 1 R activity resides with the (R)-isomer with little, if any contribution from the (S)-isomer (Deng et al., 2005; Dhawan et al., 2006) . With regard to AM5983, both isomers are active in rats, that is, substituting for the discriminative stimulus effects produced by the racemic mixture (AM5983) used for drug discrimination training, but similarly to AM2233, most activity appears attributable to the (R)-isomer (personal observation).
Current data also have heuristic value in demonstrating that AM678 (a common ingredient in 'Spice' herbal concoctions, but now banned in many countries including the United States) substitutes for THC and that the substitution is blocked by rimonabant as previously found (Järbe et al., 2010) . Coupled with other data (see Introduction), it is clear that this aminoalkylindole is bioactive and could produce marijuana-like effects, although it may not be the only synthetic cannabimimetic ingredient in any given 'Spice' formulation (Hudson et al., 2010; Vardakou et al., 2010; Atwood et al., 2011) . The binding affinity of JWH018/AM678 for CB 1 R was previously reported to be 9 nmol/l, that is, a 4-fold to 5-fold difference in comparison with THC (Aung et al., 2000) , and its in-vivo potency viz-a-viz THC in mice depended on which subtest of the 'tetrad' assay was being used for comparison (Wiley et al., 1998) . Our binding affinity estimate of 4.5 nmol/l, coupled with current and previous in-vivo drug discrimination data (Järbe et al., 2010) , would suggest that the potency difference could be as high as 8-fold. With regard to the time course, the decline in the activity at the 90-min postinjection tests suggested that the THC-like effects were waning (see also, Uchiyama et al., 2011) . Thus, a protracted time course characteristic of dimethyl, heptyl THC analogs such as HU210 or a similarly derived hexahydrocannabinol {HU243, i.e., [(6aR,10aR)-9-(hydroxymethyl)-6,6dimethyl-3-(2-methyloctan-2-yl)-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-1-ol]} was not evident for any of the current aminoalkylindoles (Järbe et al., 1981; Järbe et al., 1989; Little et al., 1989; Devane et al., 1992) .
In summary, we replicated and extended the previous observation that AM678 is a more potent cannabinergic 'THClike' ligand than WIN55212-2, also when using a higher training dose of THC. In addition, the WIN55212-2induced behavioral disruption at higher doses in the 3 mg/kg of THC group was not evident in the 1.8 mg/kg of THC group (Järbe et al., 2010) , suggesting that different training doses can be useful also in delineating mechanistic differences. The order of magnitude of the rightward shifts of the dose-response curves was larger for AM678 compared with WIN55212-2 and this finding was extended to AM5983. The shift to the right was less for WIN55212-2 compared with the shifts for AM678 and AM5983, when these CB 1 R agonists were coadministered with rimonabant, which is somewhat surprising in light of recent findings in which WIN55212-2 binding to non-CB 1 R binding sites in the mouse brain has shown to be also antagonized by rimonabant (Nguyen et al., 2010) . Currently, it is unknown if these novel non-CB 1 R binding sites are present also in the brain of other mammals such as the rat and if so, would they be differentially affected by cannabinergic ligands? Although the binding affinity for cannabinoid receptors by AM2233 is similar to that of WIN55212-2, the potency of AM2233 in eliciting 'THClike' effects was 2-fold higher than that of WIN55212-2.
AM2233 also appeared to have the shortest duration of action among the currently examined aminoalkylindoles.
